ClinicalTrials.gg
Drug

Pertuzumab/Trastuzumab/Hyaluronidase-zzxf clinical trials

Also written RG6264 and RO7198574.

studies test it
11
open now
2
in phase 3
4
first study started
2018

How each study uses Pertuzumab/Trastuzumab/Hyaluronidase-zzxf is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Pertuzumab/Trastuzumab/Hyaluronidase-zzxf studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
29 Jun 2020 · PHESGO · BLA 761170 (FDA, Drugs@FDA)
European Union
21 Dec 2020 · Phesgo · EMEA/H/C/005386 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Phesgo
10
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf
8
Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
3
Pertuzumab/Trastuzumab/Hyaluronidase-zzxf
3
PH FDC SC
3

Development codes

RG6264
6
RO7198574
6

Studies by the year they started

11 studies that test it; most in 2024 (4)

Studies that test Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, by start year
YearStudies
20181
20201
20212
20222
20231
20244

By phase

A phase 1/2 study counts in both.

Early Phase 1
1
Phase 1
1
Phase 2
6
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 5 · Other 6

Hoffmann-La Roche (4) · National Cancer Institute (NCI) (1) · Latin American Cooperative Oncology Group (1) · MedSIR (1) · Mayo Clinic (1) · Genentech, Inc. (1) · Dana-Farber Cancer Institute (1) · OHSU Knight Cancer Institute (1)

Often tested with

Tested in the same studies.

Pertuzumab (10) · Trastuzumab (7) · Ado-Trastuzumab Emtansine (3) · Paclitaxel (3) · Trastuzumab deruxtecan (2) · Entrectinib (2) · Inavolisib (2) · Alectinib (2)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3, 1 in phase 3

Studies that test Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, phase 3 first.

Studies

Open first, then newest update. How each study uses Pertuzumab/Trastuzumab/Hyaluronidase-zzxf is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 11

Given beside what is tested · 6 — Pertuzumab/Trastuzumab/Hyaluronidase-zzxf is usual care or a partner of the new treatment